During the past decade, Hopital Claude Huriez; Sce Dermatologie conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hopital Claude Huriez; Sce Dermatologie" are "Basal Cell Carcinoma" (2 trials), "Advanced BRAFV600 Wild-type Melanoma" (1 trials), "Melanoma" (1 trials) and "Metastatic Melanoma" (1 trials). Many other conditions were trialed in "Hopital Claude Huriez; Sce Dermatologie" in a lesser frequency.

Most popular intervention types in "Hopital Claude Huriez; Sce Dermatologie" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Cobimetinib" (2 trials), "Pembrolizumab" (2 trials), "Atezolizumab" (1 trials), "RO6874281" (1 trials) and "Vemurafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Claude Huriez; Sce Dermatologie" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Hopital Claude Huriez; Sce Dermatologie". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Hopital Claude Huriez; Sce Dermatologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Claude Huriez; Sce Dermatologie, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".